One candidate specifically, geftinib, an FDA-approved inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has shown promise in both acute and chronic Mtb infection, by augmenting TH1 immunity and reducing bacterial load.51 Tyrosine kinase inhibitors that have been studied extensively in tumour models, such as nilotinib, are now showing promising pharmacological expansion of protective innate immunity to mycobacterial infections.52 These compounds are attractive candidates for testing as a prophylactic anti-TB regimen in high-risk communities. The gene discussed is EGFR; the disease is tuberculosis.